Phase 1 trial of Certolizumab pegol biosimilar
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
Most Recent Events
- 01 Aug 2024 According to a Xbrane media release, the production process of the biosimilar candidate is successfully scaled up together with Xbrane's selected contract manufacturer and production of clinical material is taking place during 2024 enabling initiation of clinical trial in 2025.
- 28 Sep 2022 New trial record